Pipeline Insight: Colorectal Cancer

Growing trend towards personalized medicine

Product Code DAT04173
Publication Date October 2009
Publisher Datamonitor
Product Type Report
Pages 51
ISBN Number not applicable
Change currency
PDF £7,210.00 €8,682 $11,401 BUY >
PRINT £7,275 €8,761 $11,504 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Pipeline Insight: Colorectal Cancer

Growing trend towards personalized medicine

Introduction

CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.

Scope

  • Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates.
  • Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018.
  • Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company.
  • Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs.

Highlights

  • The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in other tumor types, where there is a shift away from standard cytotoxic therapies towards MTTs and personalized medicine.
  • The late-phase CRC pipeline consists only of MTTs. Except for one agent; all the others are being investigated in previously-treated patients. Drug developers appear to be pursuing approval for treatment in the second-line setting where barriers to market entry are lower and the high level of unmet need may facilitate a drug's uptake and approval.
  • Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the highest level of sales among the late-phase pipeline candidates in the CRC market, generating £604m by 2018 in the seven major pharmaceutical markets.

Reasons to Purchase

  • Identify key drugs and companies within the CRC pipeline based on sales forecasts to 2018 and Datamonitor drug assessment..
  • Characterize unmet need and poorly served patient subsets within the CRC market and assess the potential for pipeline products to fulfil them..
  • Segmentation and analysis of the current CRC pipeline by developmental phase, drug class, company and indication.

Contents

  • Overview
  • Catalyst
  • Summary
  • About Datamonitor Healthcare
    • About The Oncology Pharmaceutical Analysis Team
  • Executive Summary
    • Strategic Scoping And Focus
    • Datamonitor Insight Into The Colorectal Cancer Market
    • Datamonitor Pipeline Assessment Summary
    • Related Reports
    • Upcoming Related Reports
  • 1. Pipeline Overview And Dynamics
    • Key Findings
    • Pipeline Overview
    • Pipeline Summary
    • Novel Molecular Targeted Therapies Dominate The Current Late-Phase Colorectal Cancer Pipeline
    • Comparative Forecasts
    • Datamonitor Pipeline Assessment Summary
    • Key Companies Involved In The Colorectal Cancer (Crc) Pipeline
    • Amgen
    • Astrazeneca
    • Roche
    • Key R&d Company Strategies
    • Ongoing Shift Towards Molecular Targeted Therapies In Colorectal Cancer
    • Line Extensions Of Already Marketed Drugs
  • 2. Colorectal Cancer - Market Potential
    • Key Findings
    • Definition
    • Introduction
    • Colorectal Cancer Is One Of The 'Big Four' Tumors And Numbers Are Set To Rise Over The Next Decade
    • Histology
    • Risk Factors
    • Crc Is Predominantly A Disease Of The Elderly
    • People With Crc In The Family Have A High Risk Of Developing The Disease
    • Western Style Diets Contribute To Crc Incidence
    • Rise Of Crc In The Migrant Population
    • Symptoms
    • Screening And Diagnosis
    • Fecal Occult Blood Test Is The Most Commonly Used Screening Method
    • Endoscopic Methods Are Not Ideal For Crc Screening
    • Crc Screening Remains Fragmented Between Countries
    • Patient Segmentation
    • Proper Staging Is Essential To The Design Of Treatment Plans
    • Epidemiology
    • Seven Major Markets
    • Crc Cases Are Expected To Rise In Line With The Aging World Population
    • Low Detection In The Early Stages Of The Disease Results In A High Mortality Rate
    • Rest Of The World
    • Current Treatment Options
    • Surgery Remains The Primary Treatment Choice For Early-Stage Crc
    • Adjuvant Therapy Extends Disease-Free Survival In Stage Iii Patients
    • Combination Chemotherapy Is The Standard Of Care In Metastatic Disease
    • Avastin Is Used Predominantly In The Us In The First-Line Setting
    • Erbitux Is Indicated For Use In Patients With Wild-Type Kras Status
    • Vectibix Has Limited Uptake In The Treatment Of The Disease
    • Current Comparator Therapy
    • Eloxatin (Oxaliplatin; Sanofi-Aventis)
    • Unmet Need In Colorectal Cancer (Crc)
    • Better Screening Approaches Needed To Decrease Mortality Rates
    • There Is A Need For More Effective Therapies In Both Early-Stage And Advanced Disease
    • Biomarkers And The Selection Of Patients May Help Improve Outcomes
    • Target Product Profile Versus Current Level Of Attainment
  • 3. R&d Approach
    • Key Findings
    • Clinical Trial Design In Colorectal Cancer (Crc)
    • Patient Selection
    • Clinical Trial Endpoints In Oncology
    • Overall Survival
    • Disease-Free Survival
    • Overall Response Rates
    • Progression-Free Survival
    • Disease Control
    • Toxicity
  • 4. Pipeline Analysis & Forecasts: Molecular Targeted Therapies
    • Key Findings
    • Overview Of The Molecular Targeted Therapies
    • Pipeline Summary
    • Comparative Forecasts
    • Aflibercept (Vegf-Trap; Regeneron/Sanofi-Aventis)
    • Drug Overview
    • Drug Profile
    • Key Historical Events
    • Swot Analysis
    • Clinical Trial Data
    • Phase Ii Studies Show Aflibercept To Be Well Tolerated In Metastatic Crc
    • Clinical Attractiveness
    • Commercial Attractiveness
    • Datamonitor Drug Assessment Summary
    • Satisfaction Of Unmet Needs
    • Forecasts To 2018
    • Brivanib (Bristol-Myers Squibb)
    • Drug Overview
    • Drug Profile
    • Key Historical Events
    • Swot Analysis
    • Clinical Trial Data
    • The Combination Of Brivanib With Erbitux Is Tolerable And Shows Signs Of Clinical Activity
    • Retrospective Study Shows That Efficacy Of Brivanib With Erbitux Is Driven By Wild-Type Kras Patients
    • Clinical Attractiveness
    • Commercial Attractiveness
    • Datamonitor Drug Assessment Summary
    • Satisfaction Of Unmet Needs
    • Forecasts To 2018
    • Recentin (Cediranib; Astrazeneca)
    • Drug Overview
    • Drug Profile
    • Key Historical Events
    • Swot Analysis
    • Clinical Trial Data
    • Recentin Shows Disappointing Results In A Phase Ii Head-To-Head Trial Against Avastin
    • Clinical Attractiveness
    • Commercial Attractiveness
    • Datamonitor Drug Assessment Summary
    • Satisfaction Of Unmet Needs
    • Forecasts To 2018
    • Mk-0646 (Merck/Pierre Fabre)
    • Drug Overview
    • Drug Profile
    • Key Historical Events
    • Swot Analysis
    • Clinical Trial Data
    • Phase Ii Shows Mk-0646 To Be Tolerable In Metastatic Patients With Wild-Type Kras
    • Clinical Attractiveness
    • Commercial Attractiveness
    • Datamonitor Drug Assessment Summary
    • Satisfaction Of Unmet Needs
    • Forecasts To 2018
  • 5. Innovative Early-Stage Approaches
    • Key Findings
    • Overview Of Early-Stage Innovative Projects
    • Trail
    • Insulin-Like Growth Factor Receptor (Igfr)
    • Map Kinase Pathway
    • The Future Of Treatment Of Colorectal Cancer (Crc)
    • Molecular Markers Will Become An Important Part Of Therapy For Patient Selection
    • The Future Will See More Combination Therapies To Target Multiple Pathways
    • Increased Understanding Of Cancer Evolution Should Result In A Large Range Of Potential Drug Targets
    • Bibliography
    • Journals
    • Websites
    • Datamonitor Reports
  • Appendix
    • Methodology
    • Epidemiology Forecasts
    • Product Forecasts
    • Datamonitor Drug Assessment Scorecard
    • Contributing Experts
    • About Datamonitor Healthcare
    • About The Oncology Analysis Team
    • Datamonitor Consulting
    • Disclaimer
  • List Of Tables
    • Table 1: Sales Forecasts For Late-Phase Colorectal Cancer (Crc) Pipeline Products In The Seven Major Markets ($M), 2009-2018
    • Table 2: Drugs In Late-Phase Development For Colorectal Cancer (Crc), 2009
    • Table 3: Sales Forecasts For Late-Stage Colorectal Cancer (Crc) Pipeline Products In The Seven Major Markets ($M), 2009-2018
    • Table 4: Amgen's Marketed And Pipeline Oncology Portfolio, 2009
    • Table 5: Astrazeneca's Marketed And Pipeline Oncology Portfolio, 2009
    • Table 6: Roche's Marketed And Pipeline Oncology Portfolio, 2009
    • Table 7: Forecast Incidence Of Colorectal Cancer (Crc) In The Seven Major Pharmaceutical Markets, 2009-2018
    • Table 8: Molecular Targeted Therapies (Mtts) Approved For Use In Metastatic Colorectal Cancer (Crc), 2009
    • Table 9: Eloxatin (Oxaliplatin) - Drug Profile, 2009
    • Table 10: Ability Of Eloxatin To Meet Unmet Needs In The First-Line Treatment Of Metastatic Colorectal Cancer (Crc), 2009
    • Table 11: Ability Of Eloxatin To Meet Unmet Needs In The Second-Line Treatment Of Metastatic Colorectal Cancer (Crc), 2009
    • Table 12: Drugs In Late-Phase Development For Colorectal Cancer (Crc) , 2009
    • Table 15: Sales Forecasts For Late-Phase Colorectal Cancer (Crc) Pipeline Products In The Seven Major Markets ($M), 2009-2018
    • Table 16: Aflibercept - Drug Profile, 2009
    • Table 17: Aflibercept: Key Historical Events
    • Table 18: Clinical Development Of Aflibercept In Colorectal Cancer (Crc), 2009
    • Table 19: Ability Of Aflibercept To Meet Unmet Needs In Colorectal Cancer (Crc), 2009
    • Table 20: Sales Forecast For Aflibercept In Colorectal Cancer (Crc) Across The Seven Major Markets ($M), 2009-2018
    • Table 21: Brivanib - Drug Profile, 2009
    • Table 22: Brivanib: Key Historical Events
    • Table 23: Clinical Development Of Brivanib In Colorectal Cancer (Crc), 2009
    • Table 24: Phase I Results Investigating A Second-Line Or Higher Combination Of Erbitux And Brivanib In Advanced Gastrointestinal Malignancies
    • Table 25: Ability Of Brivanib To Meet Unmet Needs In Colorectal Cancer (Crc), 2009
    • Table 26: Sales Forecast For Brivanib In Colorectal Cancer (Crc) Across The Seven Major Markets($M), 2009-2018
    • Table 27: Recentin (Cediranib) - Drug Profile, 2009
    • Table 28: Recentin: Key Historical Events
    • Table 29: Clinical Development Of Recentin In Colorectal Cancer (Crc), 2009
    • Table 30: Ability Of Recentin To Meet Unmet Needs In Colorectal Cancer (Crc), 2009
    • Table 31: Sales Forecast For Recentin In Colorectal Cancer (Crc) Across The Seven Major Markets ($M), 2009-2018
    • Table 32: Mk-0646 - Drug Profile, 2009
    • Table 33: Mk-0646: Key Historical Events
    • Table 34: Clinical Development Of Mk-0646 In Colorectal Cancer (Crc), 2009
    • Table 35: Ability Of Mk-0646 To Meet Unmet Needs In Colorectal Cancer (Crc), 2009
    • Table 36: Sales Forecast For Mk-0646 In Colorectal Cancer (Crc) Across The Seven Major Markets, 2009-2018 ($M)
    • Table 37: Top 10 Early-Stage Colorectal Cancer (Crc) Drug Targets, 2009
    • Table 38: Datamonitor Drug Assessment Parameters
  • List Of Figures
    • Figure 1: Datamonitor Drug Assessment Summary For Molecular Targeted Therapies (Mtts) In Development For Colorectal Cancer (Crc), 2009
    • Figure 2: Colorectal Cancer (Crc) Pipeline Split By Development Phase And Drug Class, 2009
    • Figure 3: Datamonitor Drug Assessment Summary For Molecular Targeted Therapies (Mtts) In Development For Colorectal Cancer (Crc), 2009
    • Figure 4: Incidence And Mortality From Colorectal Cancer (Crc) In The Seven Major Pharmaceutical Markets, 2009 And 2018
    • Figure 5: Incidence Of Colorectal Cancer (Crc) In The Rest Of The World, 2009 And 2019
    • Figure 6: Datamonitor Drug Assessment Summary For Molecular Targeted Therapies In Development For Colorectal Cancer (Crc), 2009
    • Table 13: Forecast Assumptions For Molecular Targeted Therapy Colorectal Cancer (Crc) Pipeline Products Across The Seven Major Markets, 2009
    • Table 14: Forecast Assumptions For Molecular Targeted Therapy Colorectal Cancer (Crc) Pipeline Products Across The Seven Major Markets, 2009
    • Figure 7: Swot Analysis For Aflibercept, 2009
    • Figure 8: Phase Ii Data On The Second-Line Treatment Of Aflibercept In Recurrent Metastatic Colorectal Cancer (Crc) Patients Following Failure Of Standard Therapy
    • Figure 9: Datamonitor Drug Assessment Summary For Aflibercept In Colorectal Cancer (Crc), 2009
    • Figure 10: Brivanib Swot Analysis, 2009
    • Figure 11: Retrospective Analysis Evaluating Correlation Between Kras Status And Efficacy From A Phase I/Ii Study Of Brivanib In Combination With Erbitux In Patients With Advanced Or Metastatic Colorectal Cancer (Crc)
    • Figure 12: Datamonitor Drug Assessment Summary For Brivanib In Colorectal Cancer (Crc), 2009
    • Figure 13: Swot Analysis For Recentin, 2009
    • Figure 14: Phase Ii Results For Second-Line Folfox + Recentin Versus Folfox + Avastin In Metastatic Colorectal Cancer (Crc) (Horizon I)
    • Figure 15: Datamonitor Drug Assessment Summary For Recentin In Colorectal Cancer (Crc), 2009
    • Figure 16: Swot Analysis For Mk-0646, 2009
    • Figure 17: Phase Ii Study Of Mk-0646 In Second-Line Or Higher Metastatic Colorectal Cancer (Crc) Patients With Wild-Type Kras
    • Figure 18: Datamonitor Drug Assessment Summary For Mk-0646 In Colorectal Cancer (Crc), 2009
    • Figure 19: Early-Stage Colorectal Cancer Pipeline (Crc) Split By Drug Class, 2009
    • Figure 20: Datamonitor Drug Assessment Summary For Molecular Targeted Therapies In Development For Colorectal Cancer (Crc), 2009